Cargando…

Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines

BACKGROUND: An exploratory household transmission study was nested in SPECTRA, the phase 2/3 efficacy study of the adjuvanted recombinant protein-based COVID-19 vaccine SCB-2019. We compared the occurrence of confirmed COVID-19 infections between households and household contacts of infected SPECTRA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tadesse, Birkneh Tilahun, Bravo, Lulu, Marks, Florian, Aziz, Asma Binte, You, Young Ae, Sugimoto, Jonathan, Li, Ping, Garcia, Joyce, Rockhold, Frank, Clemens, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069839/ https://www.ncbi.nlm.nih.gov/pubmed/36433685 http://dx.doi.org/10.1093/cid/ciac914

Ejemplares similares

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
por: Ambrosino, Donna, et al.
Publicado: (2021)

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2022)

Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries
por: Clemens, John, et al.
Publicado: (2021)

Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Before Coronavirus Disease 2019 Vaccination Among Children 0–4 Years and Their Household Members in the SEARCh Study
por: Garcia Quesada, Maria, et al.
Publicado: (2022)

Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Magnus, Maria C, et al.
Publicado: (2022)

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant
por: Risk, Malcolm, et al.
Publicado: (2022)

Understanding Drivers of Coronavirus Disease 2019 Vaccine Hesitancy Among Blacks
por: Momplaisir, Florence, et al.
Publicado: (2021)

Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series
por: Kim, Paul S., et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019
por: Park, Hailey J, et al.
Publicado: (2023)

The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
por: Moghadas, Seyed M, et al.
Publicado: (2021)

The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2
por: Li, Jing-Xin, et al.
Publicado: (2022)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination
por: Bartsch, Sarah M, et al.
Publicado: (2021)

Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone
por: Virk, Abinash, et al.
Publicado: (2023)

Dying at Home Due to Coronavirus Disease 2019
por: Edwards, Jessie K, et al.
Publicado: (2022)

Post-Vaccination Coronavirus Disease 2019: A Case-Control Study and Genomic Analysis of 119 Breakthrough Infections in Partially Vaccinated Individuals( )
por: Baltas, Ioannis, et al.
Publicado: (2021)

Contact-Tracing Outcomes Among Household Contacts of Fully Vaccinated Coronavirus Disease 2019 (COVID-19) Patients: San Francisco, California, 29 January–2 July 2021
por: Sachdev, Darpun D, et al.
Publicado: (2021)

Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination
por: Perez, Yalile, et al.
Publicado: (2021)

Comparative Analysis of Mortality From Coronavirus Disease 2019 Across the European Union Countries and the Effects of Vaccine Coverage
por: Ziakas, Panayiotis D, et al.
Publicado: (2022)

Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic
por: Moorlag, Simone J C F M, et al.
Publicado: (2022)

Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019( )
por: Castanha, Priscila M S, et al.
Publicado: (2022)

Coronavirus Disease 2019–Associated Invasive Fungal Infection
por: Baddley, John W, et al.
Publicado: (2021)

The US Coronavirus Disease 2019 (COVID-19) Surveillance Environment: An Ecological Analysis of the Relationship of Testing Adequacy in the Context of Vaccination
por: Choi, Daesung, et al.
Publicado: (2022)

Factors Associated With Coronavirus Disease 2019 Vaccine Uptake Among Pregnant Women and Nonpregnant Women of Reproductive Age in Jamaica
por: Pinkney, Jodian A, et al.
Publicado: (2023)

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
por: Haidar, Ghady, et al.
Publicado: (2022)

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
por: Smolenov, Igor, et al.
Publicado: (2022)

Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates
por: Williams, Lucy R, et al.
Publicado: (2021)

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
por: Mwimanzi, Francis, et al.
Publicado: (2023)

Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study
por: Chin, Elizabeth T, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate
por: Clancy, Cornelius J, et al.
Publicado: (2022)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Coronavirus Disease 2019 Severity and Risk of Subsequent Cardiovascular Events
por: Wiemken, Timothy L, et al.
Publicado: (2022)

Remdesivir and Mortality in Patients With Coronavirus Disease 2019
por: Diaz, George A, et al.
Publicado: (2021)

Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study
por: Kabbani, Dima, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kpne5kapl9ip4evctcfrbgr713